We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Diclofenac Labeling Adds Warning of Hepatic Risks
Diclofenac Labeling Adds Warning of Hepatic Risks
December 11, 2009
Novartis and Endo Pharmaceuticals have revised the prescribing information for pain drug Voltaren to warn of hepatic risks such as liver failure.